Influence of Antihypertensive Treatment with Perindopril, Pindolol or Felodipin
on Plasma Leptin Concentration in Patients with Essential Hypertension

Abstract

Leptin - produced predominantly by adipocytes - is presumably also involved in pathogenesis of essential hypertension (EH). In the present study, we addressed the question whether and to what extent antihypertensive monotherapy does influence leptinemia in patients with mild or moderate EH. Forty-two EH patients were enrolled in this randomized, open-labeled study. In all subjects, plasma concentrations of leptin, insulin, glucose, cholesterol, triglycerides and creatinine were estimated twice - before and one month after initiation of monotherapy with perindopril, pindolol or felodipin, respectively. Plasma leptin concentration, in the afternoon and midnight, was significantly higher in patients with essential hypertension than in normotensive healthy subjects (p < 0.01). Therapy with perindopril or felodipin did not influence the daily profile of leptinemia or insulinemia, respectively. However, pindolol monotherapy showed a marked (p < 0.01) suppressive effect on the daily profile of leptinemia, but did not influence insulinemia. Conclusions: First, patients with essential hypertension are characterized by higher plasma leptin levels as compared with normotensive healthy subjects; second, suppressive effect of pindolol on leptinemia may be of pathophysiological relevance in the course of weight gain during β-blocker therapy.

Essential Hypertension - Leptin - Antihypertensive Treatment - Perindopril - Felodipin - Pindolol

References

• 1 Elisaf M. The treatment of coronary heart disease: an update. Part 1: An overview of the risk factors for cardiovascular disease.  Curr Med Res Opin. 2001;  17 18-28
• 2 Rimm B, Stampfer M J, Giovannucci E, Ascherio A, Spiegelman D, Colditz G A, Willett W C. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men.  Am J Epidemiol. 1995;  141 1117-1127
• 3 Kannel W B, Brand M, Skinner J J, Dawber T R, Mc Namara P M. The relation of adiposity to blood pressure and development of hypertension. The Framingham study.  Ann Intern Med. 1967;  67 48-59
• 4 MacMahon S W, Blacket R B, Macdonald G J, Hall W. Obesity, alcohol consumption and blood pressure in Australian men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study.  J Hypertens. 1984;  2 85-91
• 5 Ahima R S, Flier J S. Adipose tissue as an endocrine organ.  Trends Endocrinol Metab. 2000;  11 327-332
• 6 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J M. Positional cloning of the mouse obese gene and its human homologue.  Nature. 1994;  372 425-432
• 7 Friedman J M, Halaas J L. Leptin and the regulation of body weight in mammals.  Nature. 1998;  395 763-770
• 8 Hall J E, Shek E WM, Brands M W. Does leptin contribute to obesity hypertension?.  Curr Opin Endocrinol Diabetes. 1999;  6 225-229
• 9 Mark A L, Correia M LG, Rahmouni K, Haynes W G. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications.  J Hypertens. 2002;  20 1245-1250
• 10 Agata J, Masuda A, Takada M, Hagishiura K, Murakami H, Miyazaki Y, Shimamoto K. High plasma immunoreactive leptin level in essential hypertension.  Am J Hypertens. 1997;  10 1171-1174
• 11 Hirose H, Saito I, Tsujioka M, Mori M, Kawabe H, Saruta T. The obese gene product, leptin: possible role in obesity-related hypertension in adolescents.  J Hypertens. 1998;  16 2007-2012
• 12 Suter P M, Locher R, Häsler E, Vetter W. Is there a role of the ob gene product leptin in essential hypertension?.  Am J Hypertens. 1998;  11 1305-1311
• 13 Kokot F, Adamczak M, Wiežcek A, Cieplok J. Does leptin play a role in the pathogenesis of essential hypertension?.  Kidney Blood Pres Res. 1999;  22 154-160
• 14 Adamczak M, Kokot F, Wiežcek A. Relationship between plasma renin profile and leptinaemia in patients with essential hypertension.  J Hum Hypertens. 2000;  14 503-509
• 15 Saad M F, Riad-Gabriel M G, Khan A, Sharma A, Michael R, Jinagouda S D, Boyadjian R, Steil G M. Diurnal and ultradian rhythmicity of plasma leptin: effect of gender and adiposity.  J Clin Endocrinol Metab. 1998;  83 1706-1712
• 16 Jones D W. Body weight and blood pressure. Effects of weight reduction on hypertension.  Am J Hypertens. 1996;  9 50S-54S
• 17 Tuck M L, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure. Plasma renin activity and plasma aldosterone levels in obese patients.  N Engl J Med. 1981;  304 930-933
• 18 Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension.  J Hypertens. 1999;  17 151-183
• 19 Joint National Committee on Prevation, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Sixth report.  Arch Intern Med. 1997;  157 2413-2446
• 20 Kokot F, Wiežcek A, Schmidt-Gayk H, Marcinkowski W, Gilge U, Heidland A, Rudka R, Trembecki J. Function of endocrine organs in hemodialyzed patients on long-term erythropoietin therapy.  Artif Organs. 1995;  19 428-435
• 21 Kalsbeek A, Fliers E, Romijn J A, La Fleur S E, Wortel J, Bakker O, Endert E, Buijs R M. The suprachiasmatic nucleus generates the diurnal changes in plasma leptin levels.  Endocrinology. 2001;  142 2677-2685
• 22 Corica F, Corsonello A, Lentile R, de Gregorio T, Malara A, Artemisia A, Buemi M. Leptin and norepinephrine plasma concentrations during glucose loading in normotensive and hypertensive obese women.  Am J Hypertens. 2001;  9 50S-54S
• 23 Sonmez A, Kisa U, Uckaya G, Eyileten T, Comert B, Koc B, Kocabalkan F, Ozata M. Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension.  J Renin Angiotensin Aldosterone Syst. 2001;  2 112-116
• 24 Matsuo K, Mikami H, Ogihara T, Tuck M L. Weight reduction and pharmacologic treatment in obese hypertensives.  Am J Hypertens. 2001;  14 530-538
• 25 Kim S, Whelan J, Claycombe K, Reath D B, Moustaid-Moussa N. Angiotensin II increases leptin secretion by 3Ts-L1 and human adipocytes via a prostaglandin-independent mechanism.  J Nutr. 2002;  132 1135-1140
• 26 Malminiemi K. Long-term celiprolol therapy lowers fasting plasma leptin levels. Celiprolol Multicenter Study Group.  Cardiovasc Drugs Ther. 2000;  14 67-75
• 27 Cammisotto P G, Bukowiecki L J. Mechanisms of leptin secretion from white adipocytes.  Am J Physiol Cell Physiol. 2002;  283 C244-C250
• 28 Pinkey J H, Coppack S W, Mohamed Ali V. Effect of isoprenaline on plasma leptin and lipolysis in humans.  Clin Endocrinol (Oxf). 1998;  48 407-411
• 29 Carruli L, Ferrari S, Bertolini M, Tagliafico E, Del Rio G. Regulation of ob gene expression: evidence for epinephrine-induced suppression in human obesity.  J Clin Endocrinol Metab. 1999;  84 3309-3312
• 30 Bottner A, Eisenhofer G, Torpy D J, Ehrhart-Bornstein M, Keiser H R, Chrousos G P, Bornstein S R. Lack of leptin suppression in response to hypersecretion of catecholamines in pheochromocytoma patients.  Metabolism. 1999;  48 543-545
• 31 Sharma A M, Pischon T, Hardt S, Kunz I, Luft F C. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis.  Hypertension. 2001;  37 250-254
• 32 Kunz I, Schorr U, Klaus S, Sharma A M. Resting metabolic rate and substrate use in obesity hypertension.  Hypertension. 2000;  36 26-32
• 33 Astrup A, Simonsen L, Bulow J, Madsen J, Christensen N J. Epinephrine mediates facultative carbohydrate-induced thermogenesis in human skeletal muscle.  Am J Physiol. 1989;  257 E340-E345
• 34 Ravussin E, Pratley R E, Maffei M, Wang H, Friedman J M, Bennett P H, Bogardus C. Relatively low plasma leptin concentration precedes weight gain in Pima Indians.  Nature Med. 1997;  3 238-240
• 35 Mavri A, Stegnar M, Sabovic M. Do vaseline serum leptin levels predict weight regain after dieting in obese women?.  Diab Obes Metab. 2001;  3 293-298
• 36 Schmieder R E, Gatzka C, Schachinger H, Schobel H, Ruddel H. Obesity as a determinant for response to antihypertensive treatment.  Br Med J. 1992;  307 537-540
• 37 Ueshiba H, Tsuboi K, Miyachi Y. Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity.  Horm Metab Res. 2001;  33 167-169
• 38 Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in double-blind cross-over study in hypertensive patients.  Blood Press. 1992;  1 92-101
• 39 Reneland R, Alvarez E, Andrersson P E, Haenni A, Byberg L, Lithell H. Induction of insulin resistance by beta-blockade but not ACE-inhibition: long treatment with atenolol or trandolapril.  J Hum Hypertens. 2000;  14 175-180